Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach
Authors:
Open Access
- 6 April 2021
- journal article
- editorial
- Published by Springer Nature in British Journal of Cancer
- Vol. 125 (4) , 467-469
Abstract
Summary: Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.Keywords
Funding Information
- Cancer Research UK (C23338/A25722, C16731/A21200)
- Wellcome Trust (209213/Z/17/Z)
This publication has 12 references indexed in Scilit:
- Regulatory T cells in cancer: where are we now?Immunology, 2019
- Phosphoinositide 3‐kinase δ is a regulatory T‐cell target in cancer immunotherapyImmunology, 2019
- Intratumoral regulatory T cells: markers, subsets and their impact on anti‐tumor immunityImmunology, 2019
- The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell FunctionThe Journal of Immunology, 2019
- Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer ImmunotherapyCancer Research, 2017
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancerNature, 2014
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Cutting Edge: The Phosphoinositide 3-Kinase p110δ Is Critical for the Function of CD4+CD25+Foxp3+ Regulatory T CellsThe Journal of Immunology, 2006
- Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.2003
- The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cellsEuropean Journal of Immunology, 2003